Retinoblastoma

The patient was treated on a non-protocol treatment plan with five cycles of vincristine, carboplatin, etoposide, cyclophosphamide, and weekly intraventricular topotecan via Ommaya reservoir, followed by autologous stem cell rescue. Optical genome mapping (OGM) showed that the proximal breakpoint of the balanced inversion at 13q14.2 was within intron 17 of RB1, while the distal breakpoint at 13q31.3 did not interrupt any known genes of clinical significance. We review the various molecular techniques that aided in diagnosis of this patient and provide a summary of similar RB1-disrupting structural variants reported in the literature.

More importantly, RB1 functional status may also modulate sensitivity to additional therapeutic modalities, highlighting its broader relevance to the evolving SCLC treatment landscape. Integrating molecularly informed strategies accounting for RB1 proficiency and its transcriptional landscape will be pivotal to overcoming the long-standing therapeutic impasse in SCLC, offering a roadmap for the development of effective, precision-guided therapies.

In conclusion, LPRB shows a 50-64% penetrance rate, more likely to be paternally inherited, have unilateral presentation, and associated with hypomorphic RB1 PSVs in the terminal pRB regions. These findings support retitling 'low penetrance RB' to 'medium penetrance RB'.

Perioperative chronic stress exacerbates cognitive dysfunction after 6-h long-term isoflurane anesthesia. The activity of RbAp48/HDAC2-induced histone deacetylation modification plays a critical role in these negative effects on cognition.

MYCN gain/amplification was identified in 7.2% of enucleated unilateral retinoblastomas, all of which showed RB1 inactivation. MYCN amplification was associated with more advanced disease and more aggressive clinical and histopathological features.

These findings indicate that the presence of an HPV16 variant in a cancer does not necessarily imply increased oncogenic potency. Functional characterization is therefore essential to interpret the biological and clinical significance of HPV16 genetic diversity.

Both the BM-MSCs and tumor cells exhibited altered secretory profiles after sEV treatment. The in vitro findings provide cumulative evidence that sEV-mediated interactions contribute to a tumor-supportive milieu or premetastatic niche at the BM in Rb.

The ROS dependency of cytotoxicity was further examined using N-acetylcysteine (NAC) pretreatment. RA synergistically enhances cisplatin-induced anticancer effects in RB through oxidative stress, engagement of intrinsic (mitochondria-associated) apoptotic signaling, and reduction of tumor cell-derived inflammatory and angiogenic mediators. These findings highlight the potential of RA and Cis combination as a chemosensitizing strategy for RB therapy, warranting further in vivo evaluation.

ER-Predict represents a robust assay with potential utility in early stage HR-positive/HER2-negative breast cancer. Its consistent ability to identify high-risk patients supports further investigation as a decision-support tool to guide treatment intensification in clinically low-risk HR-positive/HER2-negative disease.

In vivo, FA-SEVs@CMG effectively inhibits RB growth while preserving retinal function. This work establishes the first SEV-based platform for noninvasive posterior segment delivery, offering a transformative strategy for treating posterior ocular diseases.

Inactivation of two tumor suppressors is required for E7 activity and our findings support that targeting either E7/RB1 or E7/PTPN14 would be of therapeutic benefit. We propose that synergistic control of cell cycle gene expression by E2F and YAP1-dependent transcription is essential for the transforming activity of oncogenic HPV.

This study provides an overview of the spectrum of germline cytogenetic alterations and clinical features in Mexican patients with RB. Our results expand the understanding of RB in this population and underscore the need for multimodal approaches for the detection and functional characterization of RB1 alterations. This study reports the largest Mexican retinoblastoma cohort with comprehensive germline RB1 characterization and high detection rates, particularly in bilateral disease.